FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer
FFNP-PET 作为晚期乳腺癌内分泌治疗方法反应的预测生物标志物
基本信息
- 批准号:10504739
- 负责人:
- 金额:$ 64.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgonistAromatase InhibitorsBiological MarkersBiopsyBreast Cancer PatientBreast Cancer cell lineCDK4 geneClinicClinicalClinical TrialsCombined Modality TherapyDNA Sequence AlterationDataDiseaseDisease ProgressionERBB2 geneESR1 geneEnrollmentEpidermal Growth Factor ReceptorEstradiolEstrogen Receptor StatusEstrogen ReceptorsEstrogen receptor positiveEstrogensFPS-FES OncogeneFulvestrantGNRH1 geneGene Expression ProfileGene MutationGenetic EngineeringGenetically Engineered MouseGenomicsGoalsHumanImageMetastatic breast cancerModelingMutateMutationPIK3CA genePatientsPharmaceutical PreparationsPhasePositron-Emission TomographyPre-Clinical ModelPrediction of Response to TherapyProgesterone ReceptorsProteinsRNAReceptor GeneReceptor SignalingRecurrenceResistanceRiskSelective Estrogen Receptor ModulatorsSignal PathwaySpecificityTamoxifenTumor-DerivedWomanXenograft Modeladjuvant endocrine therapyadvanced breast cancerarmbasechemotherapyclinical developmentexome sequencingexperiencefunctional genomicsfunctional statusgenetic signaturegenomic signaturehormone therapyimaging biomarkerimprovedindexinginhibitormTOR Inhibitormalignant breast neoplasmnovelphase II trialprecision medicinepreclinical studypredicting responsepredictive markerpublic health relevanceradiotracerreceptor expressionreceptor functionresistance mechanismresponseresponse biomarkerstandard of caretargeted treatmenttranscriptome sequencingtreatment choicetreatment responsetumortumor xenograftvirtual
项目摘要
ABSTRACT
Approximately 70% of breast cancers (BCs) are estrogen receptor (ER) positive (ER+) and human epidermal
growth factor receptor 2 negative (HER2-). Endocrine therapy (ET) reduces recurrence risk and improves
survival for many in this group. However, despite standard of care and adjuvant ET, over 20% of patients with
ER+/HER2- BC experience metastatic recurrence in the years to come, and virtually all patients with metastatic
disease eventually experience disease progression on ET due to intrinsic or acquired resistance mechanisms.
Progression on ET, however, does not preclude continued responsiveness to alternate forms of ET, including
those that combine therapies directed at ER and key signaling pathways that drive ET resistance. However,
there are currently no biomarkers that can reliably identify which patients will benefit from ET-based approaches
so that chemotherapy could be avoided or delayed. The PgR gene is highly regulated by ER at the RNA and
protein level, and thus expression of PgR in ER+ BC would be indicative of the functional status of ER and
associated predictive benefit from ET. We propose to evaluate the utility of positron emission tomography (PET)
imaging with the PgR radiotracer, [18F]fluoro-furanyl-norprogesterone (FFNP) to predict response to ET-based
therapies. In a recent phase II single-arm clinical trial, we demonstrated that FFNP-PET imaging, before and
after a one-day estradiol (E2) challenge (ΔFFNP-PET), predicted response to ET with 100% sensitivity and 100%
specificity in women with advanced ER+ BC. In this proposal, we will dissect the functional relationship between
PgR and ER and its implications for ΔFFNP-PET as a predictive imaging biomarker of ER function for the full
range of current and emerging ET-based approaches using patient-derived tumor xenografts (PDX) and
genetically engineered models, interfacing with a clinical trial. We propose three Aims. In Aim 1, we will examine
the impact of ESR1 gene mutations on ER-PgR crosstalk, PgR expression, and ΔFFNP-PET as an imaging
biomarker of ER function in preclinical models. In Aim 2, we will evaluate the utility of ΔFFNP-PET in predicting
response to single agent ET agents alone and in combination with targeted therapies in PDX models of
ER+/HER2- BC. In Aim 3, we will interface with a clinical trial to examine the impact of tumor genomics on
ΔFFNP-PET and its accuracy in predicting response to therapy in patients with metastatic ER+ HER2- breast
cancer enrolled in a phase II trial of endocrine therapy in combination with the CDK4/6 inhibitor abemaciclib.
Overall, this study aims to have a far-reaching and high impact on the implementation of precision medicine in
identifying, stratifying, and predicting response to clinically available and novel SERDs alone and in combination
with other targeted therapies in patients with advanced ER+/HER2- BC.
摘要
大约70%的乳腺癌(BC)是雌激素受体(ER)阳性(ER+)和人类表皮
生长因子受体2阴性(HER2-)。内分泌治疗(ET)降低复发风险并改善
对于这群人中的许多人来说。然而,尽管有标准的护理和辅助ET,超过20%的患者
ER+/HER2-BC在未来几年会经历转移复发,几乎所有转移的患者
由于固有或获得性耐药机制,疾病最终在ET上经历疾病进展。
然而,ET的进展并不排除对替代形式的ET的持续反应性,包括
这些药物结合了针对ER的治疗和驱动ET耐药的关键信号通路。然而,
目前还没有生物标志物可以可靠地确定哪些患者将从基于ET的方法中受益
这样就可以避免或推迟化疗。PGR基因在RNA和DNA中受ER的高度调控
ER+BC中的蛋白水平和PGR的表达可反映ER和BC的功能状态
ET带来的相关预测性益处。我们建议评估正电子发射断层扫描(PET)的实用性。
用PGR放射性示踪剂[18F]氟呋喃去甲孕酮(FFNP)显像预测ET的疗效
治疗。在最近的II期单臂临床试验中,我们展示了FFNP-PET成像,在此之前和
在一天的雌二醇(E2)激发(ΔFFNPPET)后,预测对ET的反应具有100%的敏感性和100%的敏感性
ER+BC晚期患者的特异性。在本提案中,我们将剖析
PgR和ER及其对ΔFFNP-PET作为全身性ER功能预测影像标志物的意义
目前和新兴的基于ET的方法使用患者来源的肿瘤异种移植(PDX)和
基因工程模型,与临床试验对接。我们提出了三个目标。在目标1中,我们将研究
雌激素受体1基因突变对ER-PgR串扰、PgR表达及ΔFFNP-PET显像的影响
临床前模型中内质网功能的生物标志物。在目标2中,我们将评估ΔFFNP-PET在预测中的应用
在PDX模型中单独和联合靶向治疗对单一药物和ET药物的反应
ER+/HER2-BC。在目标3中,我们将与一项临床试验对接,以检查肿瘤基因组学对
Δ-FFNP-PET及其预测ER+HER2转移性乳腺患者治疗反应的准确性
癌症患者参加了内分泌治疗联合CDK4/6抑制剂阿贝西利的II期试验。
总体而言,这项研究旨在对精准医疗在中国的实施产生深远的影响
识别、分层和预测对临床可用的和新的SERD单独和组合的反应
与其他靶向治疗联合治疗ER+/HER2-BC晚期患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FARROKH DEHDASHTI其他文献
FARROKH DEHDASHTI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FARROKH DEHDASHTI', 18)}}的其他基金
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
用于胰腺癌成像和预测标准和 CCR2 靶向治疗反应的新型 CCR2 PET
- 批准号:
10534151 - 财政年份:2019
- 资助金额:
$ 64.72万 - 项目类别:
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
用于胰腺癌成像和预测标准和 CCR2 靶向治疗反应的新型 CCR2 PET
- 批准号:
10318589 - 财政年份:2019
- 资助金额:
$ 64.72万 - 项目类别:
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
用于胰腺癌成像和预测标准和 CCR2 靶向治疗反应的新型 CCR2 PET
- 批准号:
10078604 - 财政年份:2019
- 资助金额:
$ 64.72万 - 项目类别:
A FEASIBILITY PET STUDY OF HER2 RECEPTORS IN BREAST CANCER USING 89ZR-TRASTUZUMAB
使用 89ZR-曲妥珠单抗对乳腺癌 HER2 受体进行可行性宠物研究
- 批准号:
8635832 - 财政年份:2014
- 资助金额:
$ 64.72万 - 项目类别:
A FEASIBILITY PET STUDY OF HER2 RECEPTORS IN BREAST CANCER USING 89ZR-TRASTUZUMAB
使用 89ZR-曲妥珠单抗对乳腺癌 HER2 受体进行可行性宠物研究
- 批准号:
8788511 - 财政年份:2014
- 资助金额:
$ 64.72万 - 项目类别:
Positron Emission Tomography in Prostate Cancer
前列腺癌的正电子发射断层扫描
- 批准号:
7284811 - 财政年份:2003
- 资助金额:
$ 64.72万 - 项目类别:
Positron Emission Tomography in Prostate Cancer
前列腺癌的正电子发射断层扫描
- 批准号:
7486861 - 财政年份:2003
- 资助金额:
$ 64.72万 - 项目类别:
IN VIVO ASSESSMENT OF TUMOR RECEPTOR LEVELS USING PET
使用 PET 体内评估肿瘤受体水平
- 批准号:
2330763 - 财政年份:1989
- 资助金额:
$ 64.72万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 64.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 64.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 64.72万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 64.72万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 64.72万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 64.72万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 64.72万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 64.72万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 64.72万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 64.72万 - 项目类别: